Table 2 Number of patients with CHD with appropriate assessment and treatment with specified drugs for secondary prevention at baseline and after 1 year of follow‐up.
| Number of observations | Number (%) | Estimated intra‐cluster correlation coefficients* (SE) | OR (95% CI)* | p Value | |||
|---|---|---|---|---|---|---|---|
| Intervention | Control | ||||||
| Risk factors | |||||||
| BP measured | |||||||
| Baseline | 1012 | 363 (81.8) | 460 (81.0) | ||||
| Follow‐up | 1058 | 446 (99.1) | 514 (84.5) | 0.1259 (0.0476) | 22.61 (6.47 to 70.13) | <0.0001 | |
| Cholesterol measured | |||||||
| Baseline | 892 | 228 (51.8) | 350 (77.4) | ||||
| Follow‐up | 1059 | 333 (74.0) | 403 (66.2) | 0.1271 (0.0487) | 1.21 (0.71 to 2.08) | 0.4813 | |
| Smoking status recorded | |||||||
| Baseline | 1045 | 168 (38.0) | 197 (32.7) | ||||
| Follow‐up | 1059 | 421 (93.6) | 273 (44.8) | 0.0773 (0.0333) | 33.96 (14.49 to 79.62) | <0.0001 | |
| BMI measured or weight checked | |||||||
| Baseline | 1059 | 189 (42.2) | 220 (36.0) | ||||
| Follow‐up | 1059 | 396 (88.2) | 281 (46.1) | 0.0125 (0.0412) | 10.14 (4.99 to 20.55) | <0.0001 | |
| Risk factor management | |||||||
| BP<140/85 mm Hg | |||||||
| Baseline | 1004 | 184 (43.1) | 246 (42.6) | ||||
| Follow‐up | 962 | 250 (56.1) | 223 (43.2) | 0.0002 (0.0034) | 1.61 (1.22 to 2.13) | 0.0113 | |
| Cholesterol<5 mmol/l | |||||||
| Baseline | 785 | 202 (60.5) | 255 (56.5) | ||||
| Follow‐up | 735 | 249 (74.3) | 254 (63.5) | 0.1115 (0.0214) | 1.58 (1.05 to 2.37) | 0.0314 | |
| Prescribing of secondary prevention medicines | |||||||
| Lipid‐lowering medication | |||||||
| Baseline | 1080 | 230 (49.9) | 280 (45.2) | ||||
| Follow‐up | 1080 | 275 (59.6) | 322 (52.0) | 0.0051 (0.0079) | 1.99 (1.06 to 3.74) | 0.0281 | |
| Aspirin | |||||||
| Baseline | 1080 | 300 (65.1) | 388 (62.7) | ||||
| Follow‐up | 1080 | 314 (68.1) | 411 (66.4) | 0.0021 (0.0165) | 1.08 (0.84 to 1.40) | 0.5502 | |
| Beta‐blocker† | |||||||
| Baseline | 586 | 110 (44.2) | 122 (36.2) | ||||
| Follow‐up | 586 | 125 (50.2) | 141 (41.8) | 0.0001 (0.0024) | 1.43 (1.19 to 1.99) | 0.0354 | |
| ACE inhibitor† | |||||||
| Baseline | 489 | 84 (39.4) | 117 (42.4) | ||||
| Follow‐up | 489 | 103 (48.4) | 140 (50.7) | 0.0179 (0.0194) | 0.97 (0.68 to 1.43) | 0.9301 | |
Values are numbers (percentages) unless stated otherwise.
BMI, body mass index; BP, blood pressure.
*Values adjusted for baseline, age, gender and practice. †Patients with past history of myocardial infarction only.